Liraglutide Alleviates Hepatic Steatosis by Activating the TFEB-Regulated Autophagy-Lysosomal Pathway
Liraglutide, a glucagon-like peptide-1 receptor agonist (GLP-1RA), has been demonstrated to alleviate non-alcoholic fatty liver disease (NAFLD). However, the underlying mechanism has not been fully elucidated. Increasing evidence suggests that autophagy is involved in the pathogenesis of hepatic ste...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | angličtina |
| Vydáno: |
2020
|
| On-line přístup: | https://doi.org/10.3389/fcell.2020.602574 https://www.frontiersin.org/articles/10.3389/fcell.2020.602574/pdf |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|